Buckley Wealth Management LLC Sells 582 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 22nd, 2023

Buckley Wealth Management LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,564 shares of the company’s stock after selling 582 shares during the quarter. Johnson & Johnson comprises about 3.1% of Buckley Wealth Management LLC’s investment portfolio, making the stock its 10th largest position. Buckley Wealth Management LLC’s holdings in Johnson & Johnson were worth $8,579,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of JNJ. Glassy Mountain Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $35,000. Retirement Financial Solutions LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $40,000. TD Capital Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at $48,000. VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $52,000. Finally, Iron Horse Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Up 0.3 %

Shares of Johnson & Johnson stock opened at $158.91 on Monday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The business has a 50-day moving average of $159.70 and a two-hundred day moving average of $166.20. The company has a market capitalization of $412.96 billion, a P/E ratio of 33.24, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. Johnson & Johnson’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the company earned $2.67 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on JNJ shares. Guggenheim started coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Morgan Stanley increased their target price on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Piper Sandler cut their target price on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. StockNews.com started coverage on Johnson & Johnson in a research note on Thursday. They issued a “strong-buy” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $173.00.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.